Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perseris in acute schizophrenia
NCT02109562Phase 3Completed
- Sponsor
- Indivior
- Start
- Apr 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risperidone in schizophrenia (3 arms), sponsored by Indivior. Primary endpoint: Positive and Negative Syndrome Scale Total Score at Day 57. Started Apr 2014; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02109562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109562.